Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
AbstractCancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering. View Full-Text
Share & Cite This Article
Stoiber, S.; Cadilha, B.L.; Benmebarek, M.-R.; Lesch, S.; Endres, S.; Kobold, S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells 2019, 8, 472.
Stoiber S, Cadilha BL, Benmebarek M-R, Lesch S, Endres S, Kobold S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells. 2019; 8(5):472.Chicago/Turabian Style
Stoiber, Stefan; Cadilha, Bruno L.; Benmebarek, Mohamed-Reda; Lesch, Stefanie; Endres, Stefan; Kobold, Sebastian. 2019. "Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy." Cells 8, no. 5: 472.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.